Who we are
Company overview
Cartherics is a Melbourne-based biotechnology company developing cell-based immunotherapy solutions to control cancer, endometriosis and be adapted to treat major neurological conditions. We combine the best components of immune targeting utilising gene editing, CAR technology and Extracellular Vesicles (EVs) to advance cell therapy to provide more diverse off-the-shelf treatments for patients.

Our Technology
Innovating cancer therapies and beyond
We’re developing more precise and more accessible treatment alternatives for patients with solid cancers, endometriosis and neurological conditions. Cartherics’ ‘off-the-shelf’ approach for deriving immune effector cells from gene edited induced Pluripotent Stem Cells (iPSCs) will simplify the manufacturing and distribution process, providing the potential to reach many more patients in a cost-effective way. EVs extracted from our cell products will be used as adjuncts for cancer therapy, control of endometriosis and neurological conditions such as Alzheimer’s disease.
Investment highlights
Strong scientific expertise and know-how of the manufacturing and distribution process. Portfolio of state-of-the-art intellectual property to support the commercialisation of affordable, effective CAR-iNK and CAR-T technology.
High quality and experienced management team:
Cartherics has a strong research team experienced in immunology, stem cell and cancer biology, product development, animal cancer models, patenting, product development and commercialisation.
Long-term relationships and established collaborations to leading commercial and academic groups with complementary technology to develop novel products.
Cartherics has just launched a $4 million in a state-of-the-art lab that will help strengthen the company’s research and manufacturing capabilities, as well as support the local innovation ecosystem.